Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021)

Janux Therapeutics (JANX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $77.3 million as the latest value for Q1 2021.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $77.3 million in Q1 2021 year-over-year; TTM through Mar 2021 was $77.3 million, a N/A change, with the full-year FY2020 number at $21.6 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $77.3 million for Q1 2021 at Janux Therapeutics, up from $21.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $77.3 million in Q1 2021 to a low of $17.1 million in Q2 2020.